selected scholarly activity
-
conferences
- Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer Information System (CKCis. Clinical Genitourinary Cancer. 102060-102060. 2024
- Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology. S0302-2838(24)00005-8. 2024
- Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.. Journal of Clinical Oncology. 2023
- IS A RENAL TUMOUR BENIGN OR MALIGNANT? A PREDICTION TOOL INCLUDING PATIENTS MANAGED WITH SURGERY, ABLATION, OR SURVEILLANCE. Journal of Urology. E555-E555. 2023
- OUTCOMES OF PARTIAL NEPHRECTOMY FOR NON-METASTATIC CT2 RENAL TUMORS: RESULTS FROM A CANADIAN MULTI-INSTITUTIONAL COLLABORATIVE. Journal of Urology. E166-E166. 2023
- Patients from Institutions with a Low pT2 Call Rate in Clear Cell Renal Cell Carcinoma may Experience Lower Stage-Specific Recurrence and Death. Laboratory Investigation. S1698-S1699. 2023
- ASSOCIATION BETWEEN THE SARCOMATOID STATUS AND PERCENTAGE OF SARCOMATOID ON THE CLINICAL OUTCOMES OF LOCALIZED RENAL CELL CARCINOMA POST NEPHRECTOMY. Value in Health. S52-S52. 2022
- CLINICAL OUTCOMES OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WITH OR WITHOUT SARCOMATOID DIFFERENTIATION TREATED WITH SYSTEMIC THERAPY IN REAL-WORLD CANADIAN SETTING. Value in Health. S39-S39. 2022
- The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC). Annals of Oncology. S660-S680. 2022
- 1464P The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC). Annals of Oncology. S1215-S1216. 2022
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 1133-1144. 2022
- Significant variation of tumour stage by size in clear cell renal cell carcinoma from a prospective national database with a sub-analysis for causality. Virchows Archiv. S351-S352. 2022
- OUTCOMES OF PARTIAL NEPHRECTOMY FOR NON-METASTATIC CT2 RENAL TUMORS: RESULTS FROM A CANADIAN MULTI-INSTITUTIONAL COLLABORATIVE. Journal of Urology. E394-E394. 2022
- Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology. 316-316. 2022
- Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).. Journal of Clinical Oncology. 304-304. 2022
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. TPS398-TPS398. 2022
- Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma.. Journal of Clinical Oncology. 2022
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Journal of Clinical Oncology. 2022
- Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Advances in Radiation Oncology. 2022
- PD40-07 CLINICAL OUTCOMES AND ADVERSE EVENTS AFTER FIRST-LINE TREATMENT IN METASTATIC RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. Investigative Urology. e676-e677. 2021
- Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). Kidney Cancer. 21-29. 2021
- Outcomes of Radiotherapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From The Canadian Kidney Cancer Information System (CKCis). International Journal of Radiation Oncology Biology Physics. e887-e887. 2020
- Sites of metastasis and survival in metastatic renal-cell carcinoma (mRCC): Resuits from the international mRCC Database Consortium (IMDC). Asia-Pacific Journal of Clinical Oncology. 4-4. 2020
- Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Cancer Research. NG13-NG13. 2020
- Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Journal of Clinical Oncology. 2020
- Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology. 639-639. 2020
- Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 2020
- Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 620-620. 2020
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). Journal of Clinical Oncology. 2020
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. TPS761-TPS761. 2020
- Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis). Journal of Clinical Oncology. 2020
- Real-world utilization and safety of ipilimumab plus nivolumab (I plus N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis). Journal of Clinical Oncology. 2020
- Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology. 633-633. 2020
- Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Journal of Clinical Oncology. 2020
- Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology. 642-642. 2020
- CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 885-885. 2019
- CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. v885-v885. 2019
- Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC). Annals of Oncology. 396-396. 2019
- Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC). Annals of Oncology. v396-v396. 2019
- Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology. 4516-4516. 2019
- Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology. 568-568. 2019
- Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 566-566. 2019
- Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC). Annals of Oncology. viii311-viii311. 2018
- CD73 expression in primary and metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology. 643-643. 2018
- Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 626-626. 2018
- Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. Journal of Clinical Oncology. 667-667. 2018
- Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis.. Journal of Clinical Oncology. 629-629. 2018
- Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. Journal of Clinical Oncology. e16065-e16065. 2017
- Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology. e16078-e16078. 2017
- Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology. 468-468. 2017
- Proton-pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. BJU International. 7-7. 2016
- Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience. Annals of Oncology. vi285-vi285. 2016
- Abstract P3-07-13: Outcomes of women with small, early-stage breast cancer in Manitoba from 1995-2011. Cancer Research. p3-07-13-p3-07-13. 2015
- Outcomes of women with small, early-stage breast cancer in Manitoba from 1995-2011. Cancer Research. 2015
- Optimizing the travel experiences of children and families during flight.. Journal of Investigative Medicine. S173-S173. 2006
-
journal articles
- Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of Clinical Oncology. 42:1222-1228. 2024
- Advances in the management of renal cell carcinoma. CANADIAN MEDICAL ASSOCIATION JOURNAL. 196:E235-E240. 2024
- Impact of timing of immunotherapy and cytoreductive nephrectomy on outcomes in metastatic renal cell carcinoma: Results from the CKCis database.. Journal of Clinical Oncology. 42:416-416. 2024
- Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.. Journal of Clinical Oncology. 42:393-393. 2024
- Management, outcomes and predictors of recurrence in chromophobe renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology. 42:389-389. 2024
- Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.. Journal of Clinical Oncology. 42:367-367. 2024
- Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology. 42:366-366. 2024
- Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.. Journal of Clinical Oncology. 42:382-382. 2024
- Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.. Journal of Clinical Oncology. 42:390-390. 2024
- Addressing controversial areas in the management of advanced prostate cancer in Canada. Journal of the Canadian Urological Association. 18. 2023
- Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies. European urology oncology. S2588-9311(23)00279-1. 2023
- 1893P Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC. Annals of Oncology. 34:S1018-S1019. 2023
- Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma. Hematology/Oncology Clinics of North America. 37:937-942. 2023
- Optimizing Treatment Selection in Advanced Renal Cell Carcinoma via IMDC Risk Group Stratification. European Urology. 84:379-380. 2023
- Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System. JCO Global Oncology. 9:e2300271. 2023
- How I Do It: Maintenance avelumab for advanced urothelial carcinoma.. Canadian Journal of Urology. 30:11633-11638. 2023
- Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population. Urologic Oncology: Seminars and Original Investigations. 41:328.e15-328.e23. 2023
- Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. European Urology. 84:109-116. 2023
- Corrigendum to “Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma” [Eur Urol 2023]. European Urology. 83:e166-e167. 2023
- Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.. Journal of Clinical Oncology. 41:4530-4530. 2023
- Adjuvant therapy for renal cell carcinoma. Journal of the Canadian Urological Association. 17:E154-63. 2023
- MP41-03 IS A RENAL TUMOUR BENIGN OR MALIGNANT? A PREDICTION TOOL INCLUDING PATIENTS MANAGED WITH SURGERY, ABLATION, OR SURVEILLANCE. Investigative Urology. 209:e555. 2023
- PD07-10 OUTCOMES OF PARTIAL NEPHRECTOMY FOR NON-METASTATIC cT2 RENAL TUMORS: RESULTS FROM A CANADIAN MULTI-INSTITUTIONAL COLLABORATIVE. Investigative Urology. 209:e166. 2023
- Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma. Cancer Reports. 6:e1763. 2023
- Outcomes of partial nephrectomy for non-metastatic cT2 renal tumors: Results from a Canadian multi-institutional collaborative.. Journal of Clinical Oncology. 41:690-690. 2023
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. Journal of Clinical Oncology. 41:TPS750-TPS750. 2023
- The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma. Human Vaccines and Immunotherapeutics. 19:2178217. 2023
- CO107 Clinical Outcomes of Patients With Metastatic Renal Cell Carcinoma (MRCC) With or Without Sarcomatoid Differentiation Treated With Systemic Therapy in Real-World Canadian Setting. Value in Health. 25:S39-S39. 2022
- CO177 Association Between the Sarcomatoid Status and Percentage of Sarcomatoid on the Clinical Outcomes of Localized Renal Cell Carcinoma Post Nephrectomy. Value in Health. 25:S52-S52. 2022
- Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma. Current Oncology. 29:5426-5441. 2022
- Emerging Biomarker-Guided Therapies in Prostate Cancer. Current Oncology. 29:5054-5076. 2022
- Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Advances in Radiation Oncology. 7:100899-100899. 2022
- Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. Therapeutic Advances in Medical Oncology. 14:175883592211086-175883592211086. 2022
- Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Clinical Genitourinary Cancer. 20:210-218. 2022
- Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clinical Cancer Research. 28:738-747. 2022
- The perceptions and beliefs of cannabis use among Canadian genitourinary cancer patients. Journal of the Canadian Urological Association. 16:48-54. 2022
- Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. Investigative Urology. 207:16-24. 2022
- Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. Journal for ImmunoTherapy of Cancer. 10:e003024-e003024. 2022
- Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical Genitourinary Cancer. 19:521-530. 2021
- The emerging treatment landscape of advanced urothelial carcinoma. Current opinion in supportive and palliative care. 15:247-252. 2021
- Canadian consensus forum of key controversial areas in the management of advanced prostate cancer. Journal of the Canadian Urological Association. 15:353-358. 2021
- Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma. Journal of the Canadian Urological Association. 15:281-286. 2021
- Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. JAMA Oncology. 7:773-773. 2021
- Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Journal of the Canadian Urological Association. 15:84-97. 2021
- Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Medicine. 10:1212-1221. 2021
- Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report. Current Oncology. 28:226-232. 2020
- Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. JCO Global Oncology. 6:293-306. 2020
- Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. European urology oncology. 3:695-699. 2020
- 211: Outcomes of Radiotherapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results from the Canadian Kidney Cancer Information System (CKCIS). Radiotherapy and Oncology. 150:S89-S90. 2020
- Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. European Journal of Cancer. 135:203-210. 2020
- Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Kidney Cancer. 4:119-119. 2020
- Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. European urology oncology. 3:372-381. 2020
- Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic. Journal of the Canadian Urological Association. 14:E154-E158. 2020
- Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Journal of the Canadian Urological Association. 14:123-130. 2020
- Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forum. Journal of the Canadian Urological Association. 14:E137-E149. 2020
- Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Journal of the Canadian Urological Association. 14:E115-E125. 2020
- Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology. 38:682-682. 2020
- From Famine to Feast: Treating Urinary Malignancies in the Immunotherapy Era. European Urology Focus. 6:1-2. 2020
- State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus. 6:37-40. 2020
- Response of Primary Renal Cell Carcinoma to Systemic Therapy. European Urology. 76:852-860. 2019
- Capturing recurrence in urothelial carcinoma: “more than meets the eye”. Translational Andrology and Urology. 8:S524-S527. 2019
- Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Journal of the Canadian Urological Association. 13:343-54. 2019
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications. 10:4346. 2019
- Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Journal of the Canadian Urological Association. 13:166-174. 2019
- Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. European Urology. 75:100-110. 2019
- Systemic treatments for metastatic urothelial carcinoma. Expert Opinion on Pharmacotherapy. 20:201-208. 2019
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 6:5. 2018
- Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer. 119:707-712. 2018
- The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma. Cancer immunology research. 6:758-765. 2018
- Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). British Journal of Cancer. 118:1434-1441. 2018
- Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. British Journal of Cancer. 118:1238-1242. 2018
- Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer immunology research. 6:402-408. 2018
- Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. Kidney Cancer. 2:31-36. 2018
- Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 36:607-607. 2018
- JAVELIN: avelumab another spear to fight urothelial carcinoma. The Lancet Oncology. 19:5-7. 2018
- Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 15:724-732. 2017
- Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. Journal for ImmunoTherapy of Cancer. 5:66. 2017
- Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non–Lymph Node Distant Metastasis. Clinical Genitourinary Cancer. 15:e1089-e1094. 2017
- Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget. 8:103428-103436. 2017
- Immunotherapy in the Elderly. European Urology Focus. 3:403-412. 2017
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC). Annals of Oncology. 28:v314-v315. 2017
- Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nature Communications. 8:199. 2017
- Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. Journal of Clinical Oncology. 35:4573-4573. 2017
- Outcomes of women with small, early-stage breast cancer in Manitoba from 2006-2011.. Journal of Clinical Oncology. 35:e12000-e12000. 2017
- Proton pump inhibitors (PPIs) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 35:493-493. 2017
- First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Journal of the Canadian Urological Association. 11:112-112. 2017
- Manifestations of Von Hippel Lindau syndrome: a retrospective national review. QJM - Monthly Journal of the Association of Physicians. 107:291-296. 2014
- Can incomplete metastasectomy impact renal cell carcinoma outcomes? A propensity score matching analysis from a prospective multicenter collaboration. Société Internationale d’Urologie Journal. 2:82-95.